“Vertebral fragility fractures are often asymptomatic and overlooked but are known to decrease quality of life, and can also affect mortality,” the authors wrote.
Systematic risk assessment of vertebral fractures should be considered for all patients with prostate cancer who are about to start androgen deprivation therapy (ADT), according to the authors of a recent study published in the Journal of Bone Oncology.1
In a cross-sectional study of 115 men (mean age of 73.3 years) with PCa, researchers assessed 10-year fracture risk, bone mineral density (via dual-energy X-ray absorptiometry) and possible vertebral fractures (via lateral X-rays of the thoracic and lumbar spine) prior to patients beginning androgen deprivation therapy (ADT). The study authors noted that 90 men (78.3%) in the cohort had localized PCa and 25 men (21.7%) had advanced PCa.
Researchers found low 10-year risks for hip fracture (1.7%) and osteoporotic fracture (4.4%), and a low rate of osteoporosis (4.3% as per bone mineral density testing), according to the study. However, the authors also found that 32.2% of the study cohort had at least one vertebral fracture and spinal X-rays revealed osteoporosis and/or a vertebral fracture in 33.9% of the study participants.
“Vertebral fragility fractures are often asymptomatic and overlooked but are known to decrease quality of life, and can also affect mortality,” wrote study co-author Caroline E. Wyers, PhD, who is affiliated with the Department of Internal Medicine at the VieCuri Medical Centre in Venlo, the Netherlands, and colleagues. “These findings underline the importance of systematic imaging of the spine to detect prevalent (vertebral fractures) in PCa patients at initiation of ADT, improving identification of true incident (vertebral fractures) during ADT.”
Wyers and colleagues noted that the most common locations for vertebral fractures were in the mid-thoracic (Th7-Th8) and thoracolumbar (Th12) areas of the spine. The study authors added that the majority of moderate and severe vertebral fractures occurred among men who had normal bone mineral density as well as study participants who had osteopenia.
In regard to study limitations, the study authors acknowledged that the cross-sectional study did not allow for assessment of direct correlations between risk factors and incident fractures. Wyers and colleagues noted the potential of selection bias as multiple factors, including physician and patient preferences, contribute to a decision to utilize ADT treatment. The researchers also pointed out that the predominantly Caucasian study cohort may prohibit broad extrapolation of the study findings.
1. van Oostwaard MM, van den Bergh JP, van de Wouw Y, Janssen-Heijnen M, de Jong M, Wyers CE. High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer. J Bone Oncol. 2022 ;38:100465. doi: 10.1016/j.jbo.2022.100465.